| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| TERNS PHARMACEUTICALS | 41 | 2 | +0,87 % | ||
| SAREPTA THERAPEUTICS | 19 | 1 | -0,78 % | ||
| MAZE THERAPEUTICS | 16 | - | 0,00 % | ||
| IONIS PHARMACEUTICALS | 13 | - | -6,11 % | ||
| DENALI THERAPEUTICS | 12 | - | -0,23 % | ||
| BEAM THERAPEUTICS | 8 | - | 0,00 % | ||
| BIONTECH | 7 | 13 | +0,20 % | ||
| KALVISTA PHARMACEUTICALS | 7 | 1 | -4,76 % | ||
| ANAVEX LIFE SCIENCES | 7 | - | +2,09 % | ||
| INCYTE | 6 | 25 | +0,33 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:18 | Cathie Wood's ARK trims Roku stock, buys Tempus AI | 4 | Investing.com | ||
| 00:00 | Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad U.S. payer coverage | 1 | Seeking Alpha | ||
| Mi | Tryngolza-Preisgestaltung: William Blair bestätigt Outperform-Rating für Ionis | - | Investing.com Deutsch | ||
| Mi | William Blair reiterates Ionis stock rating on Tryngolza pricing | 1 | Investing.com | ||
| Mi | Apogee Therapeutics schließt Kapitalerhöhung über 377,4 Mio. US-Dollar ab | 1 | Investing.com Deutsch | ||
| Mi | Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now | 1 | The Motley Fool | ||
| Mi | Earnings Call Transkript: Precigen meldet starkes Umsatzwachstum für 2025 dank erfolgreicher Markteinführung von PAPZIMEOS | 4 | Investing.com Deutsch | ||
| Mi | Precigen übertrifft Umsatzprognose, meldet aber Nettoverlust für 2025 | 5 | Investing.com Deutsch | ||
| Mi | Stifel hebt Kursziel für Kalvista wegen starker Ekterly-Nachfrage auf 42 US-Dollar an | 2 | Investing.com Deutsch | ||
| Mi | Kalvista stock price target raised to $42 by Stifel on Ekterly demand | 1 | Investing.com | ||
| Mi | Jefferies reiterates Kalvista stock rating on strong Ekterly sales | 1 | Investing.com | ||
| Mi | Stifel raises Denali Therapeutics price target on drug approval | 2 | Investing.com | ||
| Mi | TD Cowen downgrades Terns Pharmaceuticals stock rating on Merck acquisition | 2 | Investing.com | ||
| Mi | Rani Therapeutics names Jesper Høiland as head of strategy | 3 | Investing.com | ||
| Mi | Barclays reiterates Sarepta stock rating on siRNA platform data | 2 | Investing.com | ||
| Mi | Goldman Sachs raises Denali Therapeutics stock price target on FDA approval | 1 | Investing.com | ||
| Mi | Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization | 1 | GlobeNewswire (USA) | ||
| Mi | Barclays bestätigt Sarepta-Einstufung nach Daten zur siRNA-Plattform | 6 | Investing.com Deutsch | ||
| Mi | Goldman Sachs erhöht Kursziel für Denali Therapeutics nach FDA-Zulassung | 5 | Investing.com Deutsch | ||
| Mi | Barclays raises Ionis stock price target on Tryngolza opportunity | 5 | Investing.com |